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FIGURE 1 Myocardial Atrogin-1 Expression in Cushing Syndrome Cardiomyopathy
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(A) Myocardial atrogin-1 messenger ribonucleic acid (mRNA) expression in Cushing syndrome cardiomyopathy before and after adrenalectomy,
in idiopathic dilated cardiomyopathy (DCM) and control (CTRL) biopsy samples. (B) Inverse correlation between myocardial atrogin-1 and left
ventricular ejection fraction (EF). Blue circles indicate failing state; orange circles indicate recovery state.
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117Myocardial ﬁbrosis derives from a direct glucocor-
ticoid stimulation of ﬁbroblast activity, likely through
Smad and the transforming growth factor beta-1
pathway, and was reduced in our CS population from
11.5% to 3.1% after adrenalectomy, conﬁrming the data
obtained by speckle tracking echocardiography (3).
Along with CS, chronic steroid administration may
result in cardiac arrhythmias, remodeling, and
dysfunction that reﬂect a direct detrimental action on
cardiomyocyte structure and function. Patients on
steroids who manifest with cardiomyopathy should
consider drug discontinuation.
In conclusion, CS cardiomyopathy is a reversible
entity induced by high levels of glucocorticoids, char-
acterized by cell hypertrophy, myoﬁbrillolysis, and
myocardial ﬁbrosis that revert after adrenalectomy.
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in Ectopic Fat Stores
After Bariatric SurgeryMore than body mass index (BMI), adiposity distri-
bution in visceral area and in ectopic sites likely plays
an important role in the obesity-related risk. Ectopic
fat accumulation in the heart, the liver, and the
pancreas, namely steatosis, could induce accumula-
tion of toxic lipid intermediates leading ultimately
to organ dysfunction. Whether ectopic fat stores
are subjected to modiﬁcation through intervention
approaches is therefore crucial. The development of
noninvasive imaging has made it possible to quantify
ectopic fat stores with accuracy. Myocardial triglycer-
ide content (MTGC), hepatic triglyceride content
(HTGC), and pancreatic triglyceride content (PTGC)
can be measured in humans by proton magnetic reso-
nance spectroscopy (1). We previously demonstrated
FIGURE 1 Dynamics After Bariatric Surgery
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(A) Comparison of clinical and biological parameters at baseline, 6 months, and 32 months.
(B)Dynamics of ectopic fat depots after bariatric surgery. *p<0.05. BMI¼bodymass index;
EAT ¼ epicardial adipose tissue; HTGC ¼ hepatic triglyceride content; LV mass ¼ left
ventricular mass; MTGC ¼ myocardial triglyceride content; PTGC ¼ pancreatic triglyceride;
SCAT ¼ subcutaneous abdominal fat; VAT ¼ visceral abdominal fat.
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118that after 6 months, bariatric surgery (BS) signiﬁcantly
decreased visceral fat (VAT), HTGC, PTGC, and to a
lesser extent, epicardial adipose tissue (EAT) (1).
However, we found no signiﬁcant change in myocar-
dial fat, although it was increased at baseline (1).
Whethermore sustainedweight loss is able tomodulate
cardiac fat depots is the question we addressed here.We obtained the ethics committee’s approval to
re-evaluate ectopic fat deposits 2 or 3 years after
surgery (mean 32 months) in a group of 23 severe
obese patients who already underwent cardiac mag-
netic resonance imaging and proton magnetic reso-
nance spectroscopy. EAT, MTGC, HTGC, and PTGC
could be evaluated in 21 patients. The majority of
patients were female (81%). Mean age was 42  2
years, and mean BMI was 43.2  1.1 kg/m2. Changes in
ectopic fat levels were tested with the paired Student
t test or Wilcoxon test. The associations between
relative changes in each variable were tested with
Spearman correlation. A p value <0.05 was consid-
ered statistically signiﬁcant.
At 32 months, weight signiﬁcantly decreased from
118  15 kg to 84  18 kg and BMI from 43.2  4.3 kg/m2
to 30.7  4.9 kg/m2 (both, p < 0.0001). The mean
percentage of excess weight loss and fat mass loss at
32 months was 67  27% and 21  14%, respectively.
All patients lost weight between 6 and 32 months,
except for 5 patients who regained weight (þ10  9 kg)
and 1 patient who remained stable. We observed
complete remission of obstructive apnea syndrome
for 8 of 8 patients and diabetes remission for 6 of 8
patients. After BS, we observed an important decrease
in visceral fat (VAT 46  27%; p < 0.0001), hepatic
(HTGC 31  36%; p ¼ 0.0001) and pancreatic fat
(PTGC 44  20%; p ¼ 0.0010) compared with base-
line, but no more reduction was found at 32 months
compared with 6 months (Figure 1B). EAT (33  16%)
and subcutaneous abdominal fat (33  26%)
continued to decrease to a signiﬁcant extent
compared with their 6-month values (p ¼ 0.008 and
p ¼ 0.03, respectively). Importantly, MTGC signiﬁ-
cantly decreased at 32 months compared with base-
line (40  7%; p ¼ 0.001), and left ventricular mass
decreased at 6 months and continued to decrease be-
tween 6 and 32 months (9  10%; p ¼ 0.001). The
high-density lipoprotein/triglycerides ratio signiﬁ-
cantly increased at 32 months (Figure 1A) and was
signiﬁcantly associated with VAT, but not with MTGC
(r ¼ 0.56, p ¼ 0.02; r ¼ 0.05, p ¼ NS, respectively).
No association was observed between percentage
of ectopic fat losses and body weight changes
(p ¼ NS). Neither EAT and VAT loss nor HTGC and
MTGC loss were correlated, suggesting discrepancies
in adiposity reduction.
Our ﬁndings suggest that cardiac fat has a more
delayed response to BS than that seen in visceral fat,
or other steatoses. Signiﬁcance of triglyceride accu-
mulation in the heart is still debated (2). The con-
tracting heart has much higher metabolic demand
than other organs. Whether the presence of lipid
droplets in cardiomyocytes is detrimental or a
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119beneﬁcial compensatory response to altered systemic
metabolic changes in obesity needs further evalua-
tion. Our results also conﬁrm those obtained for
skeletal muscle, with reversal of systemic and muscle
metabolic derangements only 9 months after BS (3).
The improvement in life-style habits may have
also contributed to the late reduction in cardiac
steatosis. Compared with usual care, BS is the most
effective treatment for severe obesity, and the long-
term results regarding reduction of cardiovascular
mortality have been well established. To the best of
our knowledge, this study is the ﬁrst to show a
signiﬁcant improvement in all types of ectopic fat
depots, even cardiac steatosis, long-term after BS.
Whether these improvements participate in the
reduction of cardiovascular risk and mortality in
obese patients needs to be conﬁrmed.Ines Abdesselam
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Guidelines Stated MattersWe read with interest the recently published report of
the multicenter randomized controlled trial (RCT)
known as PRECISE-IVUS (plaque regression with
cholesterol absorption inhibitor or synthesis inhibitorevaluated by intravascular ultrasound) (1). While we
noted that coronary angiographic outcomes in those
assigned to combination statin plus ezetemibe ther-
apy compared favorably to those assigned statin
monotherapy, we were concerned that the authors
did not refer to the 2013 ACC/AHA guidelines in an
accurate fashion. Our evidence-based guidelines were
not “ﬁre and forget” as the authors write in their
discussion. Moreover, they express a serious
misconception about what the guidelines actually
said about nonstatins.
In both the guideline recommendations tables, key
ﬁgures (Figure 3 entitled Initiating Statin Therapy in
Individuals with Clinical ASCVD, and Figure 5 entitled
Statin Therapy: Monitoring Therapeutic Response
and Adherence), and in the text, we indicate clearly
what the recommendations and workﬂow are for
secondary prevention patients (2).
We think it is crucial that readers understand what
the guidelines recommended. Figure 3 shows that in
secondary prevention patients, the clinician initiates
high-intensity statin therapy if age #75 years and
without contraindications, conditions, or drug-drug
interactions inﬂuencing statin safety or a history of
statin intolerance. In addition to statin therapy, life-
style counseling was also recommended. In Figure 5
whose title alone indicates that the phrase “Fire and
Forget It” does not refer to the 2013 ACC-AHA
guidelines, it clearly shows that the guidelines
recommend a follow-up lipid panel 4 to 12 weeks after
initiation of statin therapy to assess both response to
therapy (the anticipated response to high-intensity
statin therapy was given as a $50% reduction in
low-density lipoprotein cholesterol [LDL-C]) and as a
baseline for adherence.
If the ACC/AHA cholesterol guidelines were fol-
lowed in the participants in this trial, the antici-
pated LDL-C would have been approximately in the
mid-50 mg/dl range since baseline LDL-C in both
the LZ and L group were 109.8 and 108.3 mg/dl,
respectively. Mindful that not everyone tolerates
high-intensity statins, the guidelines addressed the
situation where statin intolerance would occur. It
speciﬁcally noted: “Clinicians treating high-risk
patients who have a less-than-anticipated response
to statins, who are unable to tolerate a less-than-
recommended intensity of a statin, or who are com-
pletely statin intolerant, may consider the addition
of a nonstatin cholesterol-lowering therapy. High-risk
individuals include those with ASCVD, those with
LDL-C $190 mg/dl, and those with diabetes 40 to
75 years of age. In this situation, this guideline rec-
ommends clinicians preferentially prescribe drugs
that have been shown in RCTs to provide ASCVD
